Resveratrol, a natural polyphenolic phytochemical, has been reported to act as an antioxidant and provide anti-cancer activities. We hypothesized that resveratrol would exert a chemopreventive effect against prostate cancer via regulation of sex steroid receptor and growth factor signaling pathways. In the current study, Transgenic Adenocarcinoma Mouse Prostate (TRAMP) males were fed resveratrol (625 mg resveratrol/kg AIN-76A diet) or phytoestrogen-free, control diet (AIN-76A) starting at five weeks of age. Mechanisms of action and histopathology studies were conducted at 12 and 28 weeks of age, respectively. Resveratrol in the diet significantly reduced the incidence of poorly differentiated prostatic adenocarcinoma by 7.7-fold. 
suppressor, ER-β, provide a biochemical basis for resveratrol suppressing prostate cancer development.
Introduction
With an anticipated 27,050 deaths in 2007, prostate cancer is second only to lung cancer in cancer-related deaths among men [1] . In the prostate, pre-neoplastic lesions start to develop early in life. It has been reported that men of 20-40 years develop low-grade prostatic intraepithelial neoplasia (PIN), with a frequency of 9%, 16%, and 26%, respectively [2] . In addition, high-grade PIN, the precursor to prostate adenocarcinoma is present at a frequency of 0%, 5%, 10%, 41%, and 63% of men in their 3rd, 4th, 5th, 6th, and 7th decades, respectively [3] . According to epidemiological and laboratory data, diet, lifestyle, and environmental exposure could play a major role in the etiology of prostate cancer [4] [5] [6] [7] . Therefore, chemoprevention and the use of dietary supplements without toxicity to reduce cancer risk are extremely pertinent.
Dietary polyphenols have recently gained much attention with respect to disease prevention. Our laboratory has previously shown that the polyphenol, genistein, suppresses prostate cancer in transgenic mice [8] . We are also interested in other polyphenols with reported health benefits. Resveratrol (trans-3,4',5 trihydroxystilbene) is a phytoalexin stilbene found in grape products (e.g., wine and berries). It has been shown to reduce the risk of heart disease [9] and act as an anti-oxidant [10] and antiinflammatory agent [11] . In vitro studies have demonstrated that resveratrol has the ability to halt carcinogenesis at the initiation, promotion, and progression stages [12] . 4 Although dietary resveratrol has been shown to suppress mammary tumors in DMBAand NMU-induced mammary cancer models [13] [14] [15] , chemoprevention of prostate cancer
has not yet been reported with resveratrol in animal models.
The mechanism of action of resveratrol is not completely elucidated. In cell cultures, resveratrol can activate tumor suppressor gene p53 [16] , decrease COX-2 expression [17] , reduce NF-kappa B activation [18] , and inhibit protein tyrosine kinase activity [19] . Evidence shows that resveratrol may partially act by way of sex steroid receptor and growth factor signaling. Using prostate cancer cells, Gao et al. [20] demonstrated the ability of resveratrol to modulate androgen receptor (AR) by way of the Raf-MEK-ERK signaling pathway. Another report described resveratrol as a mixed agonist/antagonist for estrogen receptors α and β (ERs-α and β) using cytosolic extracts from MCF-7 cells and rat uteri [21] . Resveratrol has been shown to alter the insulin-like growth factor (IGF) signaling pathway at the ligand [22] and receptor [23] levels in breast cancer cells. A plethora of in vitro studies have demonstrated a reduction in cell proliferation and an increase in apoptosis in both androgen-dependent and -independent prostate cancer cell lines [16, [24] [25] [26] [27] . In vivo studies investigating the potential of resveratrol to alter sex steroid receptor and growth factor protein expression, cell proliferation, and apoptosis in the prostate have been limited. It is important to expand on the findings of in vitro studies to determine their biological relevance in an animal model prior to using dietary agents in clinical trials.
In this study, we investigated the potential of resveratrol in the diet to protect against spontaneously developing prostate cancer using the Transgenic Adenocarcinoma Mouse Prostate (TRAMP) model, an animal that closely mimics prostate cancer in at Pennsylvania State University on February 22, 2013 http://carcin.oxfordjournals.org/ Downloaded from humans [28] . In the TRAMP model, Simian Virus-40 large T antigen (SV-40 Tag) is under control of the rat probasin promoter, allowing androgen-regulated protein expression specific to the epithelium of the prostate. SV-40 Tag acts as an oncogene by interacting with retinoblastoma and p53 tumor-suppressor gene products to disrupt cell cycle regulation leading to uncontrolled proliferation. Already, the TRAMP model has been used in prostate cancer chemoprevention studies with other dietary agents [8, 29, 30] .
For this study, we hypothesized that dietary resveratrol would protect against prostate cancer development, inhibit cell proliferation, and modulate sex steroid receptor expression and IGF-signaling proteins in the prostate.
Materials and Methods

Animals
Animal care and treatments were conducted according to established guidelines and protocols approved by the Animal Care and Use Committee of the University of Alabama at Birmingham (UAB). TRAMP male and female breeders were obtained from the NCI Mouse Repository (Cancer Research Center, Frederick, MD) and used to develop this colony. Then, heterozygous transgenic females were bred with non-transgenic C57BL/6 males in order to generate heterozygous transgenic male offspring (TRAMP C57BL/6 females X C57BL/6 male breeders). At 3 weeks of age, the offspring were weaned and tails were clipped. DNA was extracted using a DNeasy Tissue Kit (Qiagen, Valencia, CA), and a PCR-based screening assay was performed to evaluate transgene incorporation [8, 28] . Dietary treatment with resveratrol was initiated at 5 weeks of age and continued until the animals were sacrificed at either 12 or 28 weeks of age for 7 cassettes, immersed in 10% formalin, dehydrated in a series of alcohol dilutions, fixed in xylene, embedded in paraffin wax, sliced into 5 µm sections, and placed on SuperfrostPlus (Fisher Scientific, Pittsburgh, PA) microscope slides as described by Folkvord et al. [31] . Sections were stained with hematoxylin and eosin. Dr. Isam Eltoum, a Board Certified Pathologist, blindly scored each coded sample using the following grading scale developed specifically for rodents as described by Wechter et al. [32] :
Grade 1 (non-cancerous), Grade 2 (low-grade PIN), Grade 3 (high-grade PIN), Grade 4 (well-differentiated lesion), Grade 5 (moderately differentiated lesion), or Grade 6 (poorly differentiated lesion).
Immunohistochemistry
Immunohistochemistry (IHC) was employed to measure Ki-67 antigen as a marker for proliferating cells in DLP and VP of 12 week old TRAMP mice (6 controls, 6 resveratroltreated). SV-40 Tag was evaluated immunohistochemically to determine if the effects of resveratrol was due to an indirect effect caused by a reduction in transgene expression or a direct biological effect on the prostate. Briefly, paraffin-embedded tissue sections on glass slides were deparaffinized in xylene and rehydrated in a gradient of alcohols.
Samples were boiled in Antigen Unmasking Solution (Vector, Burlingame, CA) for 20 minutes and then allowed to cool to room temperature. Endogenous peroxidase activity was blocked by incubating specimens in 3% H 2 O 2 at room temperature for 10 minutes.
Blocking was done using ready-to-use 2.5% Normal Horse Serum from the was semi-quantitated and localization was evaluated as described previously [33] .
Immunoblot Analyses
When Chemiluminescence (Pierce, Rockford, IL) was applied to detect the proteins of interest.
The relative intensity of the bands was measured using VersaDoc Imaging System (BioRad). Antibodies were purchased from commercial sources and detailed as follows: 
Resveratrol Blood Serum Concentrations
Since rodents are nocturnal animals and eat predominately at night, blood samples were collected in the morning. Immediately following blood collection, serum was pooled (5 mice per sample), centrifuged at 1200 X g for 15 min., and stored at - 
Resveratrol was detected by selecting its [M-H]
-molecular ions in the first quadrupole, causing collisional dissociation with nitrogen gas and selecting a specific daughter ion fragment in the third quadrupole. Selected fragment ions for resveratrol were used for specific and quantitative measurements using a multiple reaction ion monitoring-mass spectrometry approach. The cycle time for the complete group was 0.93 sec. All sera were independently analyzed in duplicate. Individual ion chromatograms representing each compound were analyzed by Analyst 1.4.1 and the area under the peak eluting in the correct time window was determined. This was normalized to the chrysin internal standard peak and the relative peak area was plotted against concentration of the standard. After fitting the response curve to a polynomial function, the relative areas for the unknowns were calculated by interpolation.
Statistics
Fisher's exact test was implemented to evaluate histopathological grade frequencies among treatment groups. For biochemical data generated from immunoblot analysis and ELISA, statistical comparisons were performed using two-sample Student t-test assuming unequal variances. We considered P < 0.05 to be significant.
Results
Resveratrol in the diet suppressesd prostate cancer development in TRAMP mice. By 28 weeks of age, TRAMP mice fed control diet developed high-grade PIN (Grade 3) and prostate cancer (Grades 4-6) at a frequency of 34% and 67%, respectively ( Table 1) .
None of the animals on control diet demonstrated normal (Grade 1) or low-grade PIN (Grade 2). Resveratrol in the diet significantly reduced the incidence of poorly differentiated prostatic adenocarcinoma (Grade 6 lesions) from 23% to 3% (7.7-fold) and delayed the progression of well differentiated (Grade 4 lesions) from 42% in controls to 62% in resveratrol treated mice. There was no statistical change in latency, number of tumors per animal, tumor weight, or number of liver, kidney, lung, or lymph node metastases between the control-and resveratrol-treated animals. Following necropsy, all animals were confirmed to be transgenic by a second round of tail-clipping and PCR.
To determine if the effect of resveratrol was directly on the probasin promoter, we measured SV-40 Tag expression. There was no difference in SV-40 Tag expression in the prostate epithelium of resveratrol-treated mice compared to controls (Fig. 1a, b) .
Resveratrol in the diet was well-tolerated and there was no evidence of toxicity.
There was no significant change in body weights in resveratrol-treated mice compared to Resveratrol decreased cell proliferation in prostates of TRAMP mice (Fig. 1c, d ).
We elected to carry out mechanistic studies at 12 weeks because TRAMP mice develop premalignant lesions by 10-12 weeks of age. Hence, this is a good sampling time to investigate cell proliferation and biomarkers as mechanisms of action prior to the time that tumors become large and compromise oxygen and nutrients to the tissue.
Furthermore, at 12 weeks these animals have been exposed to the resveratrol for seven weeks and that is shortly after PIN is measurable, but with no tumors. Using the Ki67 assay, we found that resveratrol significantly decreased cell proliferation in the DLP by 50%, in the VP by 31%, and in the entire prostate (DLP + VP combined) by 43% (Fig.   1e ).
The sex steroid receptors, AR and ER-β, but not ER-α, were regulated by dietary resveratrol. In the DLP, resveratrol in the diet caused a 2.6-fold (160%) increase in AR and a 1.65-fold (65%) increase in ER-β protein expressions, but no significant change in ER-α (Fig. 2) . In the VP of resveratrol treated TRAMP mice, AR and ER-α protein levels were not significantly different from those of controls. Because of limited sample volume, ELISA for ER-β in the VP was not possible.
The IGF-1 signaling proteins were differentially regulated by resveratrol in the DLP and VP. Resveratrol treatment significantly reduced IGF-1 in the DLP, but not in the VP (Fig. 3) . On the other hand, resveratrol resulted in up-regulated IGF-1R in the DLP, but down-regulated IGF-1R in the VP. The expression of IGF-BP3, the most abundant binding protein, was not significantly changed in the DLP or VP (data not shown). In addition, we investigated the effect of resveratrol on the major site of IGF-1 production, the liver. IGF-1, IGF-1R, and IGF-BP3 protein expression did not differ in the liver between control and treated animals (data not shown).
Resveratrol decreased the protein levels of phosphorylated ERKs 1 and 2. The protein kinases, ERK-1 (p44 MAPK) and ERK-2 (p42 MAPK) belonging to an extensively studied group of mitogen-activated protein kinases (MAPKs) were measured.
Phospho-ERK 1 (activated form) was decreased 51% in the DLP and phospho-ERKs 1 and 2 in the VP were down-regulated 34% and 43%, respectively (Fig. 4) . On the other hand, total-ERKs 1 and 2 (phosphorylated plus unphosphorylated) remained unchanged in DLP and VP (data not shown).
Resveratrol did not alter sex steroid concentrations in the blood serum. We quantified sex steroid concentrations in the blood serum of 12 and 28 week-old TRAMP mice fed control or resveratrol-containing diet. Total testosterone, free testosterone, estradiol, DHT, and SHBG did not differ significantly between resveratrol-and controltreated mice (data not shown). Resveratrol concentrations were determined from blood serum of control and resveratrol exposed mice. Total resveratrol (free and conjugated) concentration in the blood serum of 12 week old mice treated for 3 weeks with 625 mg resveratrol/kg diet was 52 ± 18 nM. 
Discussion
To our knowledge, this is the first study to show that resveratrol in the diet suppresses spontaneously developing prostate cancer in an animal model. There was an 87%
decrease (from 23% to 3%) in poorly-differentiated prostate tumors in resveratrol-fed mice compared to controls. To accompany this, there was a 42% to 62% increase in well differentiated tumors, indicating that prostate cancer was arrested at this stage; i.e., the progression of prostate tumor development was slowed down. The chemopreventive potential of resveratrol is supported by the early report of Jang et al. [12] where resveratrol induced human promyelocytic leukemia cell differentiation, inhibited the development of preneoplastic lesions in DMBA-treated mouse mammary glands in culture, and inhibited tumorigenesis in a mouse skin cancer model. In addition, three reports have shown that resveratrol suppressed chemically-induced mammary cancer in Sprague Dawley rats [13] [14] [15] .
The ability to delay the onset or diminish the progress of slowly-developing cancers such as prostate cancer by chemoprevention can have a huge impact on human lives. Clinicians and scientists are aware that men are predisposed for prostate cancer since high-grade PIN is found in 5%, 10%, 41% of men in their 4th, 5th, and 6th decades, respectively [3] . Although we may not wipe out prostate cancer, we do hope to suppress the progression of prostate cancer so men can extend their lives and quality of life.
Supporting our chemoprevention finding is the mechanistic data that resveratrol can regulate cell proliferation, sex steroid receptor protein expression, and specific growth factor signaling proteins in the prostate. A decrease in cell proliferation often accompanies a delay in cancer progression.
In young transgenic mice that demonstrate high-grade PIN, we observed a 43% reduction in the cell proliferation index in the prostate of resveratrol-treated TRAMP mice. In comparison, other studies have illustrated the anti-proliferative effects of resveratrol [25, 27] in both androgen-responsive (LnCap) and -independent (DU 145 and PC-3)
human prostate carcinoma cells lines. In our study, the reduction in proliferation most likely plays a major factor in the chemopreventive action of resveratrol. It is important to note that resveratrol in the diet did not alter the expression of SV-40 Tag in the prostates of TRAMP mice, since SV-40 Tag was readily detectable in both resveratrol-and control-treated mice. These results demonstrate that the observed effects of resveatrol is a "direct" biological effect on the prostate and not simply through the down-regulation of the transgene. After noting these biological changes, we shifted our focus to determining underlying mechanisms responsible for the changes in cell proliferation.
Androgen signaling mediated by the ligand-activated transcription factor, AR, and its corresponding ligands, testosterone and DHT, are believed to play a major role in prostate development and the etiology of prostate cancer. Historically, down-regulation in AR has been associated with a decrease in prostate cancer risk. In contrast, we showed a 2.6-fold increase in AR in the DLP and no change in the VP of 12-week-old TRAMP mice. Interestingly, Gao et al. found that resveratrol enhanced AR transactivation at lower concentrations and inhibited AR transactivation at higher concentrations in LNCap and PC-3 prostate cancer cells [20] . Our data suggest that resveratrol exerts its action, in part, by modulating the function and expression of AR in a lobe-specific manner. In regards to this tissue specificity, Prins et al. [35] reported differential regulation of AR in [36] . Two plausible causes of the up-regulation of AR in the DLP by dietary resveratrol could be a consequence of resveratrol down-regulating androgen levels or a compensation for reduced growth factor signaling (i.e., IGF signaling) in the prostate.
However, our measurement of total testosterone, free testosterone, estradiol, DHT, and SHBG did not differ significantly between resveratrol-and control-treated mice.
Therefore, the up-regulation of AR in the DLP by resveratrol does not seem to account for the chemoprevention by resveratrol.
The increase in ER-β by resveratrol may provide protection against prostate cancer and insight into the mechanism of action of resveratrol. Our data compliment a previous study using MCF-10A and MCF-7 breast cancer cell lines that showed increased ER-β mRNA levels after resveratrol treatment [37] . Moreover, the loss of ER-β expression is associated with the progression from normal prostate epithelium to PCa [38] and older ER-β knockout mice develop prostatic hyperplasia [39] . Because of the frequent loss of ER-β expression in prostate cancer [38] , it has been hypothesized that ER-β may act as a tumor suppressor [40] . It has been suggested that ER-β may be an attractive therapeutic candidate for prostate cancer intervention [41, 42] . According to Pak et al., the androgen metabolite, 5α-androstane-3β, 17β-diol binds to ER-β and suppresses the growth of the prostate [43] . Also, ER-α and ER-β are postulated to have different functions and are expressed at different levels and location in the prostate. ER-α, expressed solely in prostate stroma, has been shown to induce cell proliferation and to be elevated in prostate cancer cell lines [44] . On the other hand, ER-β, expressed in both normal stroma and secretory prostate epithelium, has been reported to exert a protective effect by inhibiting proliferation in cancer cells [45] . It is plausible that resveratrol is binding to ER-β in both the prostate stroma and epithelium or altering the levels of 5α-androstane-3β, 17β-diol and subsequently eliciting chemopreventive effects in the TRAMP model by regulating cell proliferation and differentiation. Unlike many polyphenols, resveratrol binds ER-α and ER-β with comparable relative binding affinities [46] . According to Bowers et al. [21] , resveratrol acts as an antagonist for ER-α but an agonist for ER-β. Interestingly, resveratrol-liganded ER-β has higher transcriptional activity than estradiol-liganded ER-β. Therefore, resveratrol has the potential to decrease cell proliferation by antagonizing ER-α and aid in suppressing prostate cancer by activating ER-β. and contribute to tumorigenesis. In comparing the human prostate to the rodent prostate, the former is composed of three "zones" including the central zone, periurethral transition zone, and the peripheral zone [52] . On the other hand, the rodent prostate can be divided into the ventral, anterior, and dorsolateral lobes. In the TRAMP model, prostate cancer is reported to initially develop in the DLP [36] . It has been shown that prostate cancer develops to a lesser extent and at a later date in the VP [36, 53] . In a study conducted by
Wikstrom [53] , prostate cancer (including well differentiated, moderately differentiated, and poorly differentiated tumors combined) developed 75% less in the VP than in the DLP at 36 weeks of age. Historically, it had been reported that the DLP of the rodent prostate is embryologically homologous to the peripheral zone of the human prostate, where the majority of prostate adenocarcinomas and PIN occurs [54] . However, it was recently concluded by a panel of expert pathologists that definitive data does not exist to conclude that one lobe in the rodent model is more homologous to the peripheral zone in the human than another [52] . Therefore, we focused our attention on both the DLP and VP. It is fundamentally important to differentiate between the actions of resveratrol in both lobes of the rodent. Future work should determine the similarities and differences in biochemistry between rodent prostate "lobes" and human prostate "zones" in order to correctly correlate animal studies with the clinical manifestations of human prostate cancer.
In the current study, the treatment group received 625 mg resveratrol/kg diet; a dose extrapolated from the resveratrol-mammary cancer chemoprevention study carried out by Bhat et al. [14] . This dose is equivalent to the consumption of approximately one 750 mL bottle of red wine per day. This was a proof of principle study and future studies will be designed to use lower concentrations of resveratrol as well as in combination with other polyphenols (i.e. genistein). It appears that when resveratrol is included in the diet low nM blood serum concentrations may be expected, as indicated by the 52 ± 18 nM concentration reached in our study. This is in agreement with a previous study that showed blood plasma levels reached 75 nM in mice with dietary resveratrol (23 mg/L) [55] . Micromolar concentrations of peak total resveratrol have been reported 2.5 -5 minutes post-gavage treatment, but concentrations measured at later time points (1-2 hours) were low nM or undetectable [55, 56] . Interestingly, the concentrations observed in mice were significantly lower than concentrations measured by Whitsett et al. in which female rats were fed 1000 mg resveratrol/kg diet [15] . Differences in metabolism and bioavailablity may contribute to the differences in blood serum resveratrol concentrations observed between mice and rats. Figure 2 . AR, ER-α, and ER-β protein expressions in DLP and VP of 12-week-old TRAMP mice fed AIN-76A diet (control) or AIN-76A diet supplemented with 625 mg resveratrol/kg diet starting at 5 weeks of age. Upper bands depict western blots for AR and ER-α (C: control and R: resvertrol treatments) and the lower figure is a graph of densitometry measurements from these western blot analyses plus ELISA for ER-β. Each sample consisted of three pooled prostates and each group contained 7-8 samples. Densitometry values for control mice were set at 100. There was inadequate sample to perform ELISA for ER-β in the VP. *P < 0.05 and **P < 0.001 compared to control treatment. Upper bands depict western blots for IGF-1R (C: control and R: resvertrol treatments) and the lower figure is a graph of the densitometry measurement from the western blot analysis. Each sample consisted of three pooled prostates and each group contained eight samples. Densitometry values for control mice were set at 100. * P < 0.05, ** P < 0.01, and ***P < 0.001 compared to control treatment. Upper bands depict western blots for phospho-ERKs 1 and 2 (C: control and R: resvertrol treatments) and the lower figure is a graph of densitometry measurements from these western blot analyses. Each sample consisted of three pooled prostates and each group contained 6-8 samples. Densitometry values for control mice were set at 100. * P < 0.05 and ** P < 0.01 compared to control treatment.
